Physician profile
Lisa Vinal
NPI 1316211469
$4,147.06
in general payments reported to CMS, 2019-2025
31 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $694 · 2023: $1,487 · 2024: $1,268 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,041.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $875.23 | 2022-2025 | Myrisk, Prolaris |
| Sumitomo Pharma America, INC. | $442.22 | 2023-2025 | Orgovyx, Gemtesa |
| Dendreon Pharmaceuticals LLC | $370.75 | 2023-2024 | Provenge |
| Janssen Biotech, INC. | $281.61 | 2022-2024 | Erleada, Akeega |
| Glaxosmithkline, LLC. | $228.35 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.59 | 2023-2024 | |
| Novo Nordisk INC | $172.61 | 2021-2024 | Rivfloza |
| Abbvie INC. | $114.58 | 2023-2024 | |
| Urogen Pharma, INC. | $108.93 | 2023-2024 | Jelmyto |
| Janssen Scientific Affairs, LLC | $106.61 | 2023 | Xarelto |
| Nevro Corp. | $103.40 | 2022 | |
| Boston Scientific Corporation | $102.73 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $99.68 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $89.94 | 2022 | |
| Pfizer INC. | $86.88 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $86.56 | 2023 | Repatha |
| Merck Sharp & Dohme LLC | $78.92 | 2022-2024 | Keytruda |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.71 | 2021 | |
| Esperion Therapeutics, INC. | $73.77 | 2021 | |
| Verity Pharmaceuticals INC. | $72.72 | 2023-2024 | Trelstar |
| Alexion Pharmaceuticals, INC. | $71.50 | 2023 | Ultomiris |
| Astellas Pharma US INC | $58.26 | 2023-2024 | Xtandi |
| Procept Biorobotics Corporation | $56.69 | 2024 | Aquabeam System |
| Tolmar, INC. | $48.91 | 2024 | |
| Abbott Laboratories | $42.05 | 2021 | |
| Teleflex LLC | $27.73 | 2025 | Barrigel |
| Photocure INC | $22.55 | 2024 | Cysview |
| Sanofi Pasteur INC. | $19.17 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.91 | 2024 | Adstiladrin |
| Coloplast Corp | $15.07 | 2024 | |
| Blue Earth Diagnostics | $13.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Vinal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.